Nand Singh: RO7049389 Drug Disposition
Quotient Sciences' Nand Singh featured in BJCP's article on 'Evaluation of the drug disposition of RO7049389 with in vitro data and human mass balance supported by physiologically based pharmacokinetic modeling'.
Evecxia Therapeutics Reports Favorable Data From a Phase 1 SAD/MAD Trial
Quotient Sciences has supported Evecxia with the Phase 1 two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram. Favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data was announced from the study.
Dr. Vanessa Zann: Pharmaceutical Technology Contribution
Dr. Vanessa Zann, Senior Drug Development Consultant at Quotient Sciences featured in Pharmaceutical Technology looking at the important role of early-phase biopharmaceutics.
Quotient Sciences Contributes to Clinical Pharmacology in Drug Development article, "A Phase 1 Study of Savolitinib"
Quotient Sciences experts contribute to a recent article in the American College of Clinical Pharmacology® Clinical Pharmacology in Drug Development journal that highlights the results of an ADME study of AstraZeneca's savolitinib.
Quotient Sciences have made a number of submissions through the HRA/MHRA Combined Ways of Working Pilot
The HRA and MHRA have been exploring opportunities to improve the service being offered for the approval and ongoing management of Clinical Trials of Medicinal Products (CTIMPs) and launched a pilot to test an integrated process – the Combined Ways of Working Pilot.